Gastrointestinal Cancers Symposium

The latest news from ASCO GI, including researcher interviews and physician perspective.


Meeting News CoveragePerspective

Ramucirumab plus paclitaxel improved OS, PFS in advanced gastric cancer

January 14, 2014
Patients with advanced gastric adenocarcinoma treated with ramucirumab plus paclitaxel demonstrated improved OS, PFS and quality of life compared…

Advances in gastroesophageal adenocarcinoma, pancreatic cancer highlight GI symposium

HemOnc Today, March 25, 2013
David H. Ilson, MD, PhD
The 2013 Gastrointestinal Cancers Symposium, the 10th annual international meeting organized by gastroenterologists, surgeons, and medical and…
Meeting News CoveragePerspectivePublication Exclusive

Combination therapy extends survival among patients with advanced pancreatic cancer

HemOnc Today, February 25, 2013
The addition of nab-paclitaxel to gemcitabine significantly improved survival in treatment-naïve patients with metastatic pancreatic cancer…
Perspective

Ramucirumab increased survival among patients with advanced gastric cancer

HemOnc Today, February 25, 2013
The novel drug ramucirumab significantly improved survival compared with placebo among patients with metastatic refractory gastric or…
Meeting News CoveragePerspectivePublication Exclusive

Gene expression profiling may help guide pancreatic cancer treatment

HemOnc Today, February 25, 2013
Pharmacogenomic profiling of circulating tumor cells in the bloodstream may help personalize the choice of chemotherapy for patients with pancreatic…
Meeting News CoveragePerspectivePublication Exclusive

Docetaxel extended OS for patients with relapsed esophageal, stomach cancers

HemOnc Today, March 10, 2013
Second-line treatment with docetaxel significantly improved OS among patients with advanced esophago-gastric cancer, according to results of a phase…
Meeting News CoveragePerspectivePublication Exclusive

Oral agent improved OS in Japanese patients with pancreatic cancer

HemOnc Today, February 25, 2013
Adjuvant treatment with the chemotherapy drug S-1 increased OS among Japanese patients with pancreatic cancer, according to results of a phase 3…
Meeting News CoveragePerspectivePublication Exclusive

Surgery after imatinib improved survival for patients with metastatic, recurrent GIST

HemOnc Today, February 25, 2013
Patients with metastatic or recurrent gastrointestinal stromal tumors who underwent surgery following imatinib therapy demonstrated significantly…
Meeting News Coverage

Extra-intestinal location for primary non-metastatic GIST associated with increased risk for death

HemOnc Today, February 10, 2012
2012 Gastrointestinal Cancers Symposium SAN FRANCISCO — Compared with gastrointestinal stromal tumors located within the gastrointestinal tract…
Meeting News CoveragePerspective

IP cisplatin, early start of chemotherapy associated with improved efficacy of iceMFP chemotherapy

HemOnc Today, February 10, 2012
2012 Gastrointestinal Cancers Symposium SAN FRANCISCO — Phase 3 results from the AMC 0101 study showed patients treated with iceMFP chemotherapy…